PA
Perceptive Advisors Portfolio holdings
AUM
$2.67B
This Quarter Return
+19.43%
1 Year Return
+73.17%
3 Year Return
+837.18%
5 Year Return
+928.4%
10 Year Return
+11,818.46%
AUM
$2.97B
AUM Growth
+$2.97B
(-14%)
Cap. Flow
-$158M
Cap. Flow
% of AUM
-5.33%
Top 10 Holdings %
Top 10 Hldgs %
46.1%
Holding
105
New
9
Increased
22
Reduced
25
Closed
10
Top Buys
| 1 |
Immunovant
IMVT
|
$49.6M |
| 2 |
argenx
ARGX
|
$40.1M |
| 3 |
Apogee Therapeutics
APGE
|
$38.9M |
| 4 |
Revolution Medicines
RVMD
|
$36.6M |
| 5 |
Tango Therapeutics
TNGX
|
$27.2M |
Top Sells
| 1 |
Apellis Pharmaceuticals
APLS
|
$74M |
| 2 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
$68.3M |
| 3 |
Vir Biotechnology
VIR
|
$48M |
| 4 |
Amylyx Pharmaceuticals
AMLX
|
$40M |
| 5 |
Illumina
ILMN
|
$27.2M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Astria Therapeutics
ATXS
$394M
| $16.3M | 0.54% |
2,189,462
| – | – |
|
52
Viridian Therapeutics
VRDN
$1.59B
| $15.5M | 0.52% |
1,011,205
-765,181
| -43% | -$11.7M |
|
53
Artivion
AORT
$2.04B
| $14.1M | 0.47% |
931,352
| – | – |
|
54
Establishment Labs
ESTA
$1.11B
| $13.6M | 0.45% |
277,683
-147,241
| -35% | -$7.23M |
|
55
Evolus
EOLS
$477M
| $13.6M | 0.45% |
+1,485,801
| New | +$13.6M |
|
56
Tactile Systems Technology
TCMD
$295M
| $9.94M | 0.33% |
707,159
+104,782
| +17% | +$1.47M |
|
57
Biomea Fusion
BMEA
$114M
| $9.86M | 0.33% |
716,441
| – | – |
|
58
Athira Pharma
ATHA
$15.5M
| $9.69M | 0.32% |
4,797,278
| – | – |
|
59
Natera
NTRA
$23B
| $9.65M | 0.32% |
218,178
-187,091
| -46% | -$8.28M |
|
60
Zymeworks
ZYME
$1.07B
| $9.17M | 0.31% |
1,446,123
-970,109
| -40% | -$6.15M |
|
61
Solid Biosciences
SLDB
$448M
| $8.81M | 0.29% |
3,495,933
| – | – |
|
62
Rhythm Pharmaceuticals
RYTM
$6.75B
| $8.73M | 0.29% |
+380,828
| New | +$8.73M |
|
|
CMAX
63
DELISTED
CareMax, Inc. Class A Common Stock
CMAX
| $8.11M | 0.27% |
3,823,557
+6,153
| +0.2% | +$13K |
|
64
Prothena Corp
PRTA
$452M
| $7.99M | 0.27% |
165,615
-19,000
| -10% | -$917K |
|
65
Outset Medical
OM
$245M
| $7.2M | 0.24% |
661,977
-240,383
| -27% | -$2.62M |
|
|
FUSN
66
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
| $7.15M | 0.24% |
2,751,395
| – | – |
|
|
LABP
67
DELISTED
Landos Biopharma, Inc. Common Stock
LABP
| $5.77M | 0.19% |
1,486,991
| – | – |
|
68
Terns Pharmaceuticals
TERN
$651M
| $5.41M | 0.18% |
+1,075,000
| New | +$5.41M |
|
69
Tyra Biosciences
TYRA
$657M
| $4.96M | 0.17% |
360,000
| – | – |
|
|
NBTX
70
Nanobiotix
NBTX
$415M
| $4.86M | 0.16% |
555,066
-504,734
| -48% | -$4.42M |
|
71
Axogen
AXGN
$718M
| $4.38M | 0.15% |
875,898
-588,924
| -40% | -$2.94M |
|
72
enVVeno Medical
NVNO
$15M
| $4.21M | 0.14% |
781,615
| – | – |
|
73
X4 Pharmaceuticals
XFOR
$70M
| $3.86M | 0.13% |
3,545,454
| – | – |
|
|
SLGC
74
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
| $3.59M | 0.12% |
1,500,000
| – | – |
|
75
Travere Therapeutics
TVTX
$1.75B
| $3.58M | 0.12% |
400,000
+309,252
| +341% | +$2.76M |
|